Hypothesis

We propose that chronic mTORC1 activation in aging Leydig cells drives a developmental‑like bioenergetic collapse that directly suppresses steroidogenic gene expression, making testosterone decline a downstream read‑out of a single upstream controller rather than an independent hallmark.

Mechanistic Model

mTORC1 hyperactivity inhibits AMPK, lowers NAD+ levels, and attenuates SIRT1‑PGC‑1α signaling, resulting in diminished mitochondrial biogenesis and a progressive fall in the ATP/ADP ratio. Because StAR protein shuttles cholesterol into mitochondria in an ATP‑dependent manner, reduced bioenergetic capacity limits StAR translocation and cholesterol availability for P450scc, lowering pregnenolone synthesis. Simultaneously, mTORC1‑dependent phosphorylation of FOXO1 and suppression of NR4A1 diminish transcription of StAR, CYP11A1, and HSD3B, reinforcing a steroidogenic‑deficient state. This cascade mirrors a developmental program in which proliferating progenitor cells downregulate steroidogenesis while shifting toward anaerobic glycolysis; persistent mTORC1 signaling in aged Leydig cells erroneously reactivates this program, producing a pseudo‑developmental block.

Testable Predictions

1. In Leydig cells from old mice, mTORC1 activity (p‑S6K) will be elevated, ATP/ADP ratio reduced, and StAR mitochondrial localization diminished compared with young controls.
2. Acute rapamycin treatment (or genetic Raptor knockout) in old Leydig cells will raise the ATP/ADP ratio, restore StAR mitochondrial import, and increase testosterone secretion even when LH levels are held constant.
3. Forced maintenance of a high ATP/ADP ratio via overexpression of a mitochondria‑targeted ATP synthase subunit will bypass mTORC1 inhibition and rescue steroidogenesis despite active mTORC1 signaling.
4. If the ATP/ADP ratio remains low after rapamycin, testosterone will not rise, falsifying the bioenergetic‑centric claim.

Experimental Approach

• Isolate primary Leydig cells from 3‑month and 24‑month C57BL/6 mice. Measure p‑S6K, ATP/ADP ratio (luciferase assay), mitochondrial membrane potential (JC‑1), and StAR subcellular fractionation.
• Treat cells with rapamycin (20 nM, 24 h) or vehicle; repeat assays and quantify testosterone in media by ELISA.
• In parallel, transduce old Leydig cells with AAV‑mito‑ATP5F1 to boost ATP synthesis; assess whether testosterone rises without altering p‑S6K.
• Include LH supplementation to control for gonadotropin effects.

Potential Outcomes

If rapamycin restores ATP/ADP and testosterone, and mito‑ATP5F1 rescues steroidogenesis despite sustained mTORC1 signaling, the data support the hypothesis that a single metabolic controller (mTORC1‑driven bioenergetic collapse) governs the aging‑related loss of Leydig cell function. Failure to alter testosterone despite normalized ATP/ADP would refute the model, indicating that additional, bioenergetic‑independent pathways dominate.